We are improving our search experience. To check which content you have full access to, or for advanced search, go back to the old search.

Search

Please fill in this field.
Filters applied:

Search Results

Showing 1-20 of 10,000 results
  1. Composite CYP3A (CYP3A4 and CYP3A5) phenotypes and influence on tacrolimus dose adjusted concentrations in adult heart transplant recipients

    CYP3A5 genetic variants are associated with tacrolimus metabolism. Controversy remains on whether CYP3A4 increased [* 1B (rs2740574), * 1 G ...

    Michelle Liu, Savine Hernandez, ... Sara L. Van Driest in The Pharmacogenomics Journal
    Article 15 February 2024
  2. Dose-Dependent Heart Rhythm Disturbance Occurring in Response to the Activation of Choline-Reactive Structures in Early Rat Ontogeny

    The effect of dose-dependent activation of cholinoreactive structures on the severity of sinus bradycardia occurring in some intact newborn rats...

    L. E. Dmitrieva, V. A. Sizonov, S. V. Kuznetsov in Bulletin of Experimental Biology and Medicine
    Article 01 February 2023
  3. Protective and curative effects of unconjugated bilirubin on gene expression of LOX-1 and iNOS in the heart of rats receiving high-fat diet and low dose streptozotocin: a histomorphometric approach

    Background

    Atherosclerosis is a chronic inflammatory condition affecting the large arteries and is a major cause of cardiovascular diseases (CVDs)...

    Mohammad Hasan Maleki, Omid Vakili, ... Sayed Mohammad Shafiee in Journal of Inflammation
    Article Open access 09 July 2024
  4. Sacubitril/valsartan compared to equivalent/sub-equivalent dose angiotensin receptor blocker or angiotensin-converting enzyme inhibitor in heart failure with reduced ejection fraction: a meta-analysis of randomized trials

    Purpose

    The objective of this meta-analysis is to determine how sacubitril/valsartan (SV) compares to equivalent and sub-equivalent angiotensin...

    Joseph P. Rindone, Chadwick K. Mellen in European Journal of Clinical Pharmacology
    Article 10 April 2024
  5. Maximum Tolerated Dose (MTD) Studies in Drug Toxicology Assessments

    In order to transition a new chemical entity (NCE) from the discovery arena into nonclinical development and potentially the clinic, a comprehensive...
    Yevgeniya E. Koshman, Brett R. Winters, ... Michael K. Pugsley in Drug Discovery and Evaluation: Safety and Pharmacokinetic Assays
    Living reference work entry 2023
  6. Effects of Low- and High-Dose Valproic Acid and Lamotrigine on the Heart in Female Rats

    Epilepsy is a chronic neurological disease that affects more than 50 million people worldwide. Antiepileptic drugs (AEDs) are the mainstay of...

    Azibe Yıldız, Nigar Vardı, ... Neriman Çolakoğlu in Cardiovascular Toxicology
    Article 22 January 2022
  7. Dose Range Finding (DRF) Studies in Drug Toxicology Assessments

    Early repeated dose-range finding (DRF) toxicology studies, usually conducted in rodent and non-rodent animal species, seek to provide the earliest...
    Lutfiya Miller, Brett R. Winters, ... Michael K. Pugsley in Drug Discovery and Evaluation: Safety and Pharmacokinetic Assays
    Living reference work entry 2024
  8. Dose delivery reproducibility for PBS proton treatment of breast cancer patients with and without mask immobilization

    Background

    Setup reproducibility of the tissue in the proton beam path is critical in maintaining the planned clinical target volume (CTV) dose...

    Yixiu Kang, Martin Bues, ... Mirek Fatyga in Radiation Oncology
    Article Open access 22 September 2023
  9. A retrospective study of adjuvant proton radiotherapy for breast cancer after lumpectomy: a comparison of conventional-dose and hypofractionated dose

    Purpose

    This study aimed to compare the adverse reactions of conventional-dose and hypofractionated dose of proton therapy for breast cancer.

    ...
    ZhengShan Hong, ZhaoZhi Yang, ... Qing Zhang in Radiation Oncology
    Article Open access 23 March 2023
  10. Association of effective dose to immune cells and vertebral marrow dose with hematologic toxicity during neoadjuvant chemoradiotherapy in esophageal squamous cell carcinoma

    Background

    To explore the correlation between effective dose to immune cells (EDIC) and vertebral bone marrow dose and hematologic toxicity (HT) for...

    Meng Zhang, Zhenjiang Li, Yong Yin in BMC Cancer
    Article Open access 28 June 2024
  11. Quantitative analysis of the impact of respiratory state on the heartbeat-induced movements of the heart and its substructures

    Purpose

    This study seeks to examine the influence of the heartbeat on the position, volume, and shape of the heart and its substructures during...

    Benzhe Liang, Guanzhong Gong, ... Yong Yin in Radiation Oncology
    Article Open access 05 February 2024
  12. Palliative Care for People Living with Heart Failure

    Heart failure (HF) is a clinical syndrome affecting approximately 5 million people worldwide, causing a significant symptom burden and reducing both...
    Piotr Z. Sobanski, Sarah J. Goodlin in Textbook of Palliative Care
    Living reference work entry 2024
  13. Daily dose evaluation based on corrected CBCTs for breast cancer patients: accuracy of dose and complication risk assessment

    Objectives

    The goal of this study is to validate different CBCT correction methods to select the superior method that can be used for dose evaluation...

    Vincent C. Hamming, Sebastian Andersson, ... Nanna M. Sijtsema in Radiation Oncology
    Article Open access 12 December 2022
  14. Recent successes in heart failure treatment

    Remarkable recent advances have revolutionized the field of heart failure. Survival has improved among individuals with heart failure and a reduced...

    Carolyn S. P. Lam, Kieran F. Docherty, ... Torbjørn Omland in Nature Medicine
    Article 09 October 2023
  15. Δ9-Tetrahydrocannabinol Effects on Respiration and Heart Rate Across Route of Administration in Female and Male Mice

    The physiological impact of cannabinoid receptor agonists is of great public health interest due to their increased use in recreational and...

    Lucas T. Laudermilk, Julie A. Marusich, Jenny L. Wiley in Cardiovascular Toxicology
    Article 20 September 2023
  16. Evaluation of risk due to chronic low dose ionizing radiation exposure on the birth prevalence of congenital heart diseases (CHD) among the newborns from high-level natural radiation areas of Kerala coast, India

    Background

    The human population residing in monazite bearing Kerala coast are exposed to chronic low dose and low dose rate external gamma radiation...

    K. R. Sudheer, P. K. Mohammad Koya, ... Birajalaxmi Das in Genes and Environment
    Article Open access 04 January 2022
  17. Comparison of different dose accumulation strategies to estimate organ doses after stereotactic magnetic resonance-guided adaptive radiotherapy

    Introduction

    Re-irradiation is frequently performed in the era of precision oncology, but previous doses to organs-at-risk (OAR) must be assessed to...

    Sebastian Regnery, Lukas Leiner, ... Juliane Hörner-Rieber in Radiation Oncology
    Article Open access 29 May 2023
  18. LRRC10 regulates mammalian cardiomyocyte cell cycle during heart regeneration

    Leucine-rich repeat containing 10 (LRRC10) is a cardiomyocyte-specific protein, but its role in cardiac biology is little understood. Recently Lrrc10...

    Rebecca J. Salamon, Megan C. McKeon, ... Ahmed I. Mahmoud in npj Regenerative Medicine
    Article Open access 28 July 2023
  19. Long-term low-dose acetylsalicylic use shows protective potential for the development of both vascular dementia and Alzheimer’s disease in patients with coronary heart disease but not in other individuals from the general population: results from two large cohort studies

    Background

    No population-based cohort study investigated a potential inverse association between long-term low-dose acetylsalicylic acid (ASA) use and...

    Thi Ngoc Mai Nguyen, Li-Ju Chen, ... Ben Schöttker in Alzheimer's Research & Therapy
    Article Open access 28 May 2022
  20. A randomized phase II study of full dose gemcitabine versus reduced dose gemcitabine and nab-paclitaxel in vulnerable patients with non-resectable pancreatic cancer (DPCG-01)

    Background

    According to current evidence, the best treatment for fit patients with non-resectable pancreatic cancer (PC) is combination chemotherapy,...

    Louise Skau Rasmussen, Stine B. Winther, ... Morten Ladekarl in BMC Cancer
    Article Open access 16 June 2023
Did you find what you were looking for? Share feedback.